Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06020833
PHASE1/PHASE2
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Sponsor: Peking Union Medical College Hospital
View on ClinicalTrials.gov
Summary
Roxadustat has been approved for low-risk MDS clinical trials, but the trial results are not available. For refractory low-risk MDS, the effective rate of roxadustat treatment is about 20-30%, and roxadustat combined with retinoic acid may have better efficacy in the treatment of refractory low-risk MDS.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2023-08
Completion Date
2026-12
Last Updated
2023-09-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
Roxadustat in combination with retinoic acid
Roxadustat 150mg po qod combined with retinoic acid 20mg po bid